CYTK Q1 2023 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+301.8% YoY

Gross Profit

-$75M-1621.7% margin

Operating Income

-$124M-2698.3% margin

Net Income

-$131M-2846.1% margin

EPS (Diluted)

$-1.36

QoQ Revenue Growth

+135.7%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$123M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$890M

Total Liabilities

$1.1B

Stockholders' Equity

-$229M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$1M	+301.8%
Gross Profit	-$75M	-$45M	-67.0%
Operating Income	-$124M	-$78M	-59.9%
Net Income	-$131M	-$89M	-46.8%

Revenue Segments

Milestone

$3M54%

Research And Development

$2M46%